sellModerate cluster of 310b5-1 plan
A. Sinclair Dunlop sold $738k of APLS
director at Apellis Pharmaceuticals, Inc.. 31,092 shares at an average of $23.72, traded Oct 10, 2025, filed Oct 15, 2025.
Warning score
51Value
$738k
31,092 shares
Holdings after
3,837
-89% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +21Trade size$738k at market
- +20Share of holdings soldSold 89% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-240563, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 24, 2025 | JOther Common Stock10b5-1 | -4,787 | $0.00 | $0 | 153,606 | Oct 15, 2025 |
| Oct 10, 2025 | SOpen-market sale Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -31,092 | $23.72 | $738k | 3,837 | Oct 15, 2025 |
| Oct 10, 2025 | JOther Common Stockindirect: Indirect Owner (Epidarex)10b5-1 | -3,837 | $0.00 | $0 | 0 | Oct 15, 2025 |
Related signals
Other insiders at Apellis Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | APLSsell Apellis Pharmaceuticals, Inc. | Mark Jeffrey DeLong Chief Business & Strat Officer | $8,153 368 shares | -0% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | David O. Watson General Counsel | $170k 7,832 shares | -8% | |
| 49Moderate | Apellis Pharmaceuticals, Inc. | Timothy Eugene Sullivan Chief Financial Officer | $224k 10,287 shares | -10% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | Nur Nicholson Chief Technical Officer | $168k 7,725 shares | -10% | |
| 59Moderate | Apellis Pharmaceuticals, Inc. | Cedric Francois Chief Executive Officer | $592k 27,192 shares | -9% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | Pascal Deschatelets Chief Scientific Officer | $129k 5,928 shares | -1% | |
| 38Weak | Apellis Pharmaceuticals, Inc. | Mark Jeffrey DeLong Chief Business & Strat Officer | $73k 3,371 shares | -4% | |
| 36Weak | Apellis Pharmaceuticals, Inc. | James George Chopas VP/Chief Accounting Officer | $45k 2,064 shares | -4% | |
| 37Weak | Apellis Pharmaceuticals, Inc. | Caroline Baumal Chief Medical Officer | $61k 2,797 shares | -3% | |
| 37Weak | Apellis Pharmaceuticals, Inc. | David O. Watson General Counsel | $49k 2,475 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.